Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francis Metz

Internal Medicine Morgan City, LA Medical Doctor

NPI 1447257001 CMS profile 155777

1126 Marguerite St, Morgan City, LA 70380

Open in the dashboard

General payments

$13,860

870 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Francis Metz of Morgan City, LA is reported in the CMS Open Payments database as having received $13,860 across 870 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,106 122
2024 General $1,965 116
2023 General $1,964 124
2022 General $1,958 125
2021 General $2,454 152
2020 General $1,708 108
2019 General $1,705 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francis Metz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Francis Metz were reported at $2,106. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Francis Metz Internal Medicine median Middle half National median
2019 $1,705 $159 $48–$570 $163
2020 $1,708 $119 $33–$402 $114
2021 $2,454 $135 $37–$521 $132
2022 $1,958 $141 $42–$496 $149
2023 $1,964 $149 $45–$519 $160
2024 $1,965 $154 $47–$537 $164
2025 $2,106 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,572 108 payments
  2. GlaxoSmithKline, LLC. $1,279 87 payments
  3. Pfizer Inc. $937 69 payments
  4. Novo Nordisk Inc $865 55 payments
  5. AstraZeneca Pharmaceuticals LP $860 39 payments
  6. Janssen Pharmaceuticals, Inc $658 41 payments
  7. Merck Sharp & Dohme Corporation $527 35 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $509 31 payments
  9. Astellas Pharma US Inc $508 25 payments
  10. Amgen Inc. $428 27 payments
  11. Other $5,717 353 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,728 866 payments
  2. Education $132 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,025 70 payments
  2. RYBELSUS $773 50 payments
  3. Ozempic $753 49 payments
  4. FARXIGA $707 30 payments
  5. XARELTO $658 41 payments
  6. UBRELVY $616 47 payments
  7. QULIPTA $486 35 payments
  8. ELIQUIS $416 33 payments
  9. STEGLATRO $413 28 payments
  10. BELSOMRA $393 26 payments
  11. Other $12,552 790 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 258 drugs

Part D claims

23,580

Median for Internal Medicine: 777

Drug cost

$2,234,653

Median for Internal Medicine: $73,373

Branded share of claims

23.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 359 $383,764
Eliquis Apixaban Brand 306 $176,635
Ingrezza Valbenazine Tosylate Brand 24 $141,177
Jardiance Empagliflozin Brand 184 $126,142
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 134 $110,777
Synjardy Xr Empagliflozin/Metformin Hcl Brand 117 $98,523
Farxiga Dapagliflozin Propanediol Brand 119 $84,392
Xarelto Rivaroxaban Brand 106 $59,375
Ozempic Semaglutide Brand 51 $52,381
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 36 $41,148

The 10 drugs with the highest cost, of 258 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$172,634

Of which drugs: $219

Medicare patients

560

Average age 76

Services billed

4,503

278 women, 282 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 43%
Diabetes 39%
Depression 29%
COPD 27%
Atrial fibrillation 26%
Chronic kidney disease 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 1,409 $128
Injection, methylprednisolone acetate, 80 mg J1040 Office 21 21 $68
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 15 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $165
$165 134 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $99
$99 119 —
UBRELVY
  • AbbVie, Inc. $96
$96 — —
VRAYLAR
  • AbbVie, Inc. $87
$87 15 —
QULIPTA
  • AbbVie, Inc. $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

870 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record